Eaton Vance Management’s Dr. Reddy's Laboratories RDY Stock Holding History

Eaton Vance Management’s Portfolio RDY Stock Details RDY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-5,160	Closed	-$68K	–	2501
2021 Q4	$68K	Buy	5,160 +310	+6%	+$3.91K	﹤0.01%	1980
2021 Q3	$63K	Sell	4,850 -30,780	-86%	-$410K	﹤0.01%	1497
2021 Q2	$523K	Buy	35,630 +30,115	+546%	+$421K	﹤0.01%	1338
2021 Q1	$68K	Buy	+5,515	New	+$70.8K	﹤0.01%	1713

Other funds holding RDY

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Eaton Vance Management's RDY Position: Q1 2022 in Review

Eaton Vance Management sold out of Dr. Reddy's Laboratories (RDY) in Q1 2022, closing a stake of 5,160 shares — an estimated $68K sold.

Eaton Vance Management first reported a position in RDY in Q1 2021 and held it in 4 quarters. The position peaked at $523K in Q2 2021. 146 funds tracked by Wall St. Rank hold RDY as of Q1 2022.

Eaton Vance Management reported no remaining Dr. Reddy's Laboratories position as of Q1 2022 after selling out during the quarter.
Eaton Vance Management sold 5,160 Dr. Reddy's Laboratories shares in Q1 2022, an estimated $68K.
Eaton Vance Management first reported a position in Dr. Reddy's Laboratories in Q1 2021 and held it in 4 quarters.
Eaton Vance Management's Dr. Reddy's Laboratories position peaked at $523K in Q2 2021.
146 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q1 2022.

Based on Eaton Vance Management's 13F filing for Q1 2022, filed 16 May 2022.